GLP-1, or {glucagon-like|glucagon like|glucagon) peptide-1, is rapidly gaining a major focus in healthcare studies, largely due to its notable impact on treating conditions such as type 2 diabetes and excess body fat. Ongoing trials have demonstrated that more than glucose management, GLP-1 agonists offer promise for cardiovascular well-being and e